COVend brings together 13 partners from 11 different countries. The consortium includes clinicians from the internal medicine, infectiology and intensive care, experts in ICT (smart tools, data analytics and modelling), cell biology, biomarkers and other areas. It comprises 5 hospitals with sufficiently large patient numbers to conduct the proposed ph II/III trial and forward-thinking medical doctors from Central, North, South, West and notably East Europe, 3 SMEs with one owning full rights and freedom to operate to further develop FX06 (F4-Pharma), the second developing AI-based open-source software architectures and tools (MiDa) and the third SME partner specialised EU project management and outreach (accelCH). Their expertise is complemented by four academic groups with expert knowledge in biomarkers and clinical trial management (Fraunhofer), endothelial cell assessment (UCD), predictive modelling and decision-support tools (TAU) and socio-economic analyses (UMCG). Finally, ESAIC, acting as an A-CRO for the sites locally, represents approx. 200,000 clinical staff all over Europe. Hence, our public private partnership covers all key stakeholder groups and has all the required expertise, experience, and capacity to deliver a new biomarker and AI-enhanced therapy – FX06.